Coomans Marijke B, Peeters Marthe C M, Koekkoek Johan A F, Schoones Jan W, Reijneveld Jaap, Taphoorn Martin J B, Dirven Linda
Department of Neurology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Department of Neurology, Haaglanden Medical Center, 2262 BA The Hague, The Netherlands.
Cancers (Basel). 2020 Nov 24;12(12):3502. doi: 10.3390/cancers12123502.
Health-related quality of life (HRQoL) has become an increasingly important patient-reported outcome in glioma studies. Ideally, collected HRQoL data should be exploited to the full, with proper analytical methods. This systematic review aimed to provide an overview on how HRQoL data is currently evaluated in glioma studies, focusing on the research objectives and statistical analyses of HRQoL data.
A systematic literature search in the databases PubMed, Embase, Web of Science and Cochrane was conducted up to 5 June 2020. Articles were selected based on predetermined inclusion criteria and information on study design, HRQoL instrument, HRQoL research objective and statistical methods were extracted.
A total of 170 articles describing 154 unique studies were eligible, in which 17 different HRQoL instruments were used. HRQoL was the primary outcome in 62% of the included articles, and 51% investigated ≥1 research question with respect to HRQoL, for which various analytical methods were used. In only 42% of the articles analyzing HRQoL results over time, the minimally clinical important difference was reported and interpreted. Eighty-six percent of articles reported HRQoL results at a group level only, and not at the individual patient level.
Currently, the assessment and analysis of HRQoL outcomes in glioma studies is highly variable. Opportunities to maximize information obtained with HRQoL data include appropriate and complementary analyses at both the group and individual level, comprehensive reporting of HRQoL results in separate articles or supplementary material, and adherence to existing guidelines about the assessment, analysis and reporting of patient-reported outcomes.
在胶质瘤研究中，健康相关生活质量（HRQoL）已成为越来越重要的患者报告结局。理想情况下，应采用适当的分析方法充分利用收集到的HRQoL数据。本系统评价旨在概述目前胶质瘤研究中如何评估HRQoL数据，重点关注HRQoL数据的研究目的和统计分析。
截至2020年6月5日，在PubMed、Embase、Web of Science和Cochrane数据库中进行了系统的文献检索。根据预先确定的纳入标准选择文章，并提取有关研究设计、HRQoL工具、HRQoL研究目的和统计方法的信息。
共有170篇描述154项独特研究的文章符合条件，其中使用了17种不同的HRQoL工具。在纳入文章中，62%将HRQoL作为主要结局，51%针对HRQoL研究了≥1个研究问题，并使用了各种分析方法。在分析HRQoL随时间变化结果的文章中，只有42%报告并解释了最小临床重要差异。86%的文章仅在组水平报告了HRQoL结果，而未在个体患者水平报告。
目前，胶质瘤研究中HRQoL结局的评估和分析差异很大。充分利用HRQoL数据获取信息的机会包括在组水平和个体水平进行适当且互补的分析，在单独文章或补充材料中全面报告HRQoL结果，以及遵守关于患者报告结局评估、分析和报告的现有指南。
